Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG



Status:Recruiting
Conditions:Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:18 - Any
Updated:3/31/2019
Start Date:March 7, 2018
End Date:September 2019
Contact:Gary Ingenito, MD, PhD
Email:gingenito@catalystpharma.com
Phone:305-420-3200

Use our guide to learn which trials are right for you!

A Randomized, Placebo-control, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients With MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients

Efficacy and safety of amifampridine phosphate in improving the activities of daily living
for patients with antibody positive MuSK myasthenia gravis.

Randomized, double-blind, placebo-controlled, parallel group study is designed to evaluate
the safety, tolerability and efficacy of amifampridine phosphate in patients with MuSK-MG. In
addition, a sample of AChR-MG patients will be assess for efficacy and safety of
amifampridine phosphate. Planned duration of participation for each patient is at least 38
days, excluding the screening period. Eligible patients will be titrated to an efficacious
dose of amifampridine phosphate and those who demonstrate improvement will be randomized to
either placebo or amifampridine, in a double-blind fashion, for 10 days.

Inclusion Criteria:

1. Willing and able to provide written informed consent after the nature of the study has
been explained and before the start of any research-related procedures.

2. Male or female ≥18 years of age.

3. Positive serologic test for anti-MuSK antibodies or anti-AChR antibodies as confirmed
at Screening or by previous antibody test, with report available.

4. Confirmatory EMG or EMG report.

5. Myasthenia Gravis Foundation of America (MGFA) Class II to IV at Screening.

6. MG-ADL score of ≥6 at Screening, with more than 50% of this score attributed to
non-ocular items.

7. Patients receiving steroids or pyridostigmine should not have any modification of drug
regimen during the month before Screening.

8. Female patients of childbearing potential must have a negative pregnancy test (serum
human chorionic gonadotropin [HCG] at screening); and must practice an effective,
reliable contraceptive regimen during the study and for up to 30 days following
discontinuation of treatment.

9. Ability to participate in the study based on overall health of the patient and disease
prognosis, as applicable, in the opinion of the Investigator; and able to comply with
all requirements of the protocol, including completion of study questionnaires.

Exclusion Criteria:

1. Epilepsy and currently on medication.

2. Concomitant use of medicinal products with a known potential to cause QTc
prolongation.

3. Patients with long QT syndromes.

4. History of thymectomy within 12 months before Screening.

5. An electrocardiogram (ECG) within 6 months before starting treatment that shows
clinically significant abnormalities, in the opinion of the Investigator.

6. Breastfeeding or pregnant at Screening or planning to become pregnant at any time
during the study.

7. Patients receiving immunomodulatory treatment (e.g. plasma exchange [PE], therapeutic
plasma exchange [TPE], intravenous immunoglobulin G [IVIG]) should not have any
treatment in the previous 4 weeks prior to Randomization or at any time during the
study.

8. Use of rituximab or other similar biologic medications for immunomodulation within 6
months prior to Screening.

9. Treatment with an investigational drug (other than amifampridine) or device within 30
days before Screening or while participating in this study.

10. Any medical condition that, in the opinion of the Investigator, might interfere with
the patient's participation in the study, poses an added risk for the patient, or
confound the assessment of the patient.

11. History of drug allergy to any pyridine-containing substances or any amifampridine
excipient(s).
We found this trial at
16
sites
Los Angeles, California 90033
213) 740-2311
University of Southern California The University of Southern California is one of the world’s leading...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
5050 Anthony Wayne Dr
Detroit, Michigan 48201
(313) 577-2424
Phone: 313-966-9047
Wayne State University Founded in 1868, Wayne State University is a nationally recognized metropolitan research...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Chicago, Illinois 60612
Phone: 312-563-6015
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2600 Clifton Ave
Cincinnati, Ohio 45267
(513) 556-6000
Phone: 513-558-0269
University of Cincinnati The University of Cincinnati offers students a balance of educational excellence and...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
11100 Euclid Avenue
Cleveland, Ohio 44106
Phone: 216-983-5144
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Columbia, Missouri 65212
?
mi
from
Columbia, MO
Click here to add this to my saved trials
281 W. Lane Ave
Columbus, Ohio 43210
(614) 292-6446
Phone: 614-685-5815
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Detroit, Michigan 48202
Phone: 313-916-4121
?
mi
from
Detroit, MI
Click here to add this to my saved trials
East Lansing, Michigan 48824
Phone: 517-884-2274
?
mi
from
East Lansing, MI
Click here to add this to my saved trials
Fairway, Kansas 66205
?
mi
from
Fairway, KS
Click here to add this to my saved trials
Houston, Texas 77030
Phone: 713-441-5192
?
mi
from
Houston, TX
Click here to add this to my saved trials
Irvine, California 92868
?
mi
from
Irvine, CA
Click here to add this to my saved trials
Memphis, Tennessee 38104
?
mi
from
Memphis, TN
Click here to add this to my saved trials
530 Northeast Glen Oak Avenue
Peoria, Illinois 61637
Phone: 309-655-3448
?
mi
from
Peoria, IL
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Phone: 215-294-9132
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials